Ultragenyx Pharmaceutical Priced, Nasdaq: RARE
Clinical-stage biotech developing treatments for rare metabolic genetic diseases.
Industry: Health Care
First Day Return: +101.2%
RARE
Clinical-stage biotech developing treatments for rare metabolic genetic diseases.
| IPO Data | |
|---|---|
| IPO Date | 01/30/2014 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $121 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Novato, CA, United States |
| Founded | 2010 |
| Employees at IPO | 59 |
| Website www.ultragenyx.com | |
IPO News for Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical (RARE) Performance
